Institut Paoli-Calmettes, Centre de Lutte Contre le Cancer, Université d'Aix-Marseille, INSERM CBT 1409, Centre d'Investigations Cliniques en Biothérapie, F-13009 Marseille, France.
Laboratory of Translational Immunology and Department of Hematology, UMC Utrecht, 3508GA Utrecht, Netherlands.
Sci Transl Med. 2018 Apr 11;10(436). doi: 10.1126/scitranslmed.aap9630.
Over the last 60 years, more than a million patients received hematopoietic cell transplantation. Having incorporated multiple changes in clinical practices, it remains a complex procedure facing a dual challenge: cure of the underlying disease and prevention of relapse while controlling potentially severe complications. Improved understanding of underlying biological processes resulted in the design of innovative therapies engineered from defined cell populations and testing of these therapies as addition or substitution at virtually every step of the procedure. This review provides an overview of these developments, many of them now applied outside the historical field of hematopoietic cell transplantation.
在过去的 60 年里，有超过 100 万名患者接受了造血细胞移植。该疗法在临床实践中经历了多次变革，目前仍然是一种复杂的程序，面临着双重挑战：既要治愈潜在疾病，又要预防复发，同时还要控制可能出现的严重并发症。人们对潜在生物学过程的认识不断加深，推动了从明确的细胞群体设计创新疗法，并在该程序的几乎每一步都进行这些疗法的添加或替代测试。本综述概述了这些发展，其中许多现在已经应用于造血细胞移植的历史领域之外。
